LEVOTHYROXINE MANUFACTURERS HAVE THREE YEARS TO OBTAIN NDA APPROVAL UNDER FDA POLICY; AGENCY CITES POTENCY AND STABILITY PROBLEMS WITH THYROID PRODUCTS
Executive Summary
FDA is giving manufacturers of levothyroxine sodium three years to obtain NDA approval for their products under a new drug policy announced Aug. 14.
You may also be interested in...
Tighter Levothyroxine Standards Are Only First Step To Higher Quality – Cmte.
Tightening levothyroxine potency standards will not address underlying concerns about the quality of the manufacturing process for such products, members of the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees said
Tighter Levothyroxine Standards Are Only First Step To Higher Quality – Cmte.
Tightening levothyroxine potency standards will not address underlying concerns about the quality of the manufacturing process for such products, members of the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees said
Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says